Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Pediatric Disease Priority Review Voucher
Fierce Pharma
Bavarian Nordic's $160M PRV price reflects new realities
The value of PRVs appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program.
Angus Liu
Jun 18, 2025 11:47am
PTC sells priority review voucher from Kebilidi nod for $150M
Nov 27, 2024 8:35am
Acadia makes $100M profit from $150M pediatric voucher sale
Nov 6, 2024 9:36am
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 7:00am
BridgeBio adds another $110M to coffers with voucher sale
May 13, 2022 9:45am
Jazz grabs Spark’s priority review voucher for $110M
Apr 30, 2018 10:50am
